Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06988618

Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults

The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Prurigo Nodularis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Galderma Investigational Site # 6374, Karlsruhe, Baden-Wurttemberg, Germany

Loading trial locations.

About this study

This prospective, multicenter, non-interventional study (NIS) seeks to evaluate PN treatment with nemolizumab (Nemluvio®) in adults over an approximately 12 month period using physician assessments in routine clinical practice and PRO measures. Treatment with nemolizumab will be determined solely by the participant's physician prior to study enrollment. No additional visits, procedures, or laboratory tests are required outside of routine clinical practice.

The visit structure is not defined by the study protocol but is determined by routine medical practice. The visit schedule is intended to facilitate a systematic data assessment according to clinical routine. A sub-study will be completed in Germany and the UK at selected sites in which participants will complete the Peak pruritus (PP) numerical rating scale (NRS) and Sleep Disturbance (SD) NRS on a daily basis from Day -1 to Day 14. Data collection will occur remotely and no clinic visits will be required.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants who, according to the treating physician's decision and in line with the local package label, are newly initiated on nemolizumab (Nemluvio®) for the treatment of PN.
  • Participants greater than or equal to (>=) 18 years of age.
  • Participants who signed the written informed consent form (ICF).

Exclusion criteria

  • Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label;
  • Participants who received treatment with a drug under clinical development/ investigation within 3 months prior to baseline.
  • Participants who received nemolizumab previously.
  • Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.

Treatment and study plan

Primary outcomes

  1. Investigator Global Assessment-chronic Prurigo (IGA-CPG stage) at Month 6

    Time frame: At 6 month

    The IGA-CPG stage is an instrument used to assess the overall number and thickness of chronic prurigo lesions at a given time point, as determined by the physician. In this scale, nodules, papules, plaques, and other PN lesions are defined as pruriginous lesions or chronic prurigo lesions. A single score will be determined by the physician as follows: 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), or 4 (severe). A higher score indicates severe chronic prurigo.

  2. Peak Pruritus Numerical Rating Scale (PP NRS) at Month 6

    Time frame: At 6 month

    The PP NRS is a single-question validated PRO assessment that participants will use to report the maximum intensity of their pruritus (itch). The PP NRS consists of the following question: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Here, a lower score indicates a better outcome.

Secondary outcomes

  1. Investigator Global Assessment-chronic Prurigo (IGA-CPG stage) Up to Month 12

    Time frame: Up to 12 months

    The IGA-CPG stage is an instrument used to assess the overall number and thickness of chronic prurigo lesions at a given time point, as determined by the physician. In this scale, nodules, papules, plaques, and other PN lesions are defined as pruriginous lesions or chronic prurigo lesions. A single score will be determined by the physician as follows: 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), or 4 (severe). A higher score indicates severe chronic prurigo.

  2. Prurigo Activity Score (PAS) Up to Month 12

    Time frame: Up to 12 months

    The PAS is a physician-assessed tool to monitor the distribution and activity of chronic prurigo lesions. This includes a count of the number of lesions in a representative area and a calculated staging (stage 0 to stage 4) based on the percentage of lesions with excoriations/crusts and healed lesions compared to all lesions. A higher score indicates higher level of activity.

  3. Peak Pruritus Numerical Rating Scale (PP NRS) Up to Month 12

    Time frame: Up to 12 months

    The PP NRS is a single-question validated PRO assessment that participants will use to report the maximum intensity of their pruritus (itch). The PP NRS consists of the following question: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Here, a lower score indicates a better outcome.

  4. Sleep Disturbance Numerical Rating Scale (SD NRS) Up to Month 12

    Time frame: Up to 12 months

    The SD NRS is a single-item PRO for quantifying sleep disturbance that has been validated in PN participants. The SD NRS consists of the following question: "On a scale of 0 to 10, with 0 being 'no sleep loss related to the symptoms of my skin disease (prurigo nodularis)' and 10 being 'I did not sleep at all due to the symptoms of my skin disease (prurigo nodularis)', how would you rate your sleep last night". Here, a lower score indicates a better outcome.

Study contacts

Contact information is provided by the study sponsor or research team.

Galderma Research and Development

CONTACT

[email protected]

817-961-5000

Sponsors and collaborators

Lead sponsor

Galderma R&D

Industry

Registry information

Acronym: RE-UNITE PN

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
May 25, 2025
Registry last updated
Jun 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.